MX2017007458A - Derivados del factor 21 de crecimiento de fibroblastos (fgf21) y sus usos. - Google Patents
Derivados del factor 21 de crecimiento de fibroblastos (fgf21) y sus usos.Info
- Publication number
- MX2017007458A MX2017007458A MX2017007458A MX2017007458A MX2017007458A MX 2017007458 A MX2017007458 A MX 2017007458A MX 2017007458 A MX2017007458 A MX 2017007458A MX 2017007458 A MX2017007458 A MX 2017007458A MX 2017007458 A MX2017007458 A MX 2017007458A
- Authority
- MX
- Mexico
- Prior art keywords
- fgf21
- derivatives
- fgf21 derivatives
- relates
- cysteine
- Prior art date
Links
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 title abstract 5
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 title abstract 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 2
- 108091008794 FGF receptors Proteins 0.000 abstract 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 abstract 1
- 101000846529 Homo sapiens Fibroblast growth factor 21 Proteins 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 102000056713 human FGF21 Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se relaciona con un derivado de una proteína FGF21 que tiene un residuo cisteína en una posición que corresponde a la posición 167, 169, 170, 171, 172, 173, 174, 175 y en particular la posición 180 o la posición 181 de FGF21 humano maduro y derivados de los mismos que tienen una cadena lateral unida a esta cisteína. Los derivados de FGF21 de la invención presentan una potencia elevada hacia los receptores de FGF. La invención también se relaciona con composiciones farmacéuticas que comprenden a estos derivados de FGF21 y a excipientes farmacéuticamente aceptables así como el uso médico de los derivados de FGF21.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14199935 | 2014-12-23 | ||
| PCT/EP2015/080969 WO2016102562A1 (en) | 2014-12-23 | 2015-12-22 | Fgf21 derivatives and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017007458A true MX2017007458A (es) | 2017-08-10 |
| MX377044B MX377044B (es) | 2025-03-07 |
Family
ID=52130150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017007458A MX377044B (es) | 2014-12-23 | 2015-12-22 | Derivados del factor 21 de crecimiento de fibroblastos (fgf21) y sus usos. |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9744213B2 (es) |
| EP (1) | EP3236991B1 (es) |
| JP (1) | JP6727210B2 (es) |
| KR (1) | KR102427527B1 (es) |
| CN (1) | CN107108709B (es) |
| AR (1) | AR103246A1 (es) |
| AU (1) | AU2015371056B2 (es) |
| DK (1) | DK3236991T3 (es) |
| ES (1) | ES2742503T3 (es) |
| HK (1) | HK1246156B (es) |
| HR (1) | HRP20191292T1 (es) |
| HU (1) | HUE044783T2 (es) |
| IL (1) | IL252438B (es) |
| MX (1) | MX377044B (es) |
| MY (1) | MY181181A (es) |
| PL (1) | PL3236991T3 (es) |
| PT (1) | PT3236991T (es) |
| RS (1) | RS59154B1 (es) |
| RU (1) | RU2729011C2 (es) |
| SA (1) | SA517381673B1 (es) |
| SI (1) | SI3236991T1 (es) |
| TW (2) | TWI681966B (es) |
| WO (1) | WO2016102562A1 (es) |
| ZA (1) | ZA201703768B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3463412A1 (en) | 2016-05-24 | 2019-04-10 | Novo Nordisk A/S | Mic-1 compounds and use thereof |
| CN106421753A (zh) * | 2016-10-19 | 2017-02-22 | 哈尔滨医科大学 | 重组人成纤维细胞生长因子‑21在制备预防和治疗缺血性心律失常药物中的应用 |
| TWI710377B (zh) * | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Ｍｉｃ－１化合物及其用途 |
| EP3678687B1 (en) | 2017-09-04 | 2022-08-17 | 89Bio Ltd. | Mutant fgf-21 peptide conjugates and uses thereof |
| MX2021000016A (es) | 2018-07-03 | 2021-03-09 | Bristol Myers Squibb Co | Formulaciones de factor de crecimiento de fibroblastos (fgf-21). |
| US11427623B1 (en) | 2019-05-28 | 2022-08-30 | 89Bio Ltd. | Methods of treatment using mutant FGF-21 peptide conjugates |
| WO2021139744A1 (en) | 2020-01-11 | 2021-07-15 | Beijing Ql Biopharmaceutical Co., Ltd. | Conjugates of fusion proteins of glp-1 and fgf21 |
| JP2024517329A (ja) | 2021-05-11 | 2024-04-19 | サイトカイ・ファーマ・アーペーエス | インターロイキン－２２の治療的誘導体 |
| EP4089108A1 (en) | 2021-05-11 | 2022-11-16 | CytoKi Pharma ApS | Therapeutic derivatives of interleukin-22 |
| KR102631925B1 (ko) * | 2021-06-10 | 2024-02-01 | 토드제약 주식회사 | 신규 fgf21 변이체 개발 및 이의 생산기법과 용도 |
| EP4288461A4 (en) | 2021-07-14 | 2025-07-02 | Beijing Ql Biopharmaceutical Co Ltd | FUSION POLYPEPTIDES FOR METABOLIC DISORDERS |
| GB2625224A (en) * | 2021-09-08 | 2024-06-12 | Leto Laboratories Co Ltd | FGF21 mutant protein and use thereof |
| KR102749341B1 (ko) | 2022-07-08 | 2025-01-06 | 노보 노르디스크 에이/에스 | FVIII(a)를 치환할 수 있는 매우 강력한 ISVD 화합물 |
| WO2024008904A2 (en) | 2022-07-08 | 2024-01-11 | Novo Nordisk A/S | Highly potent isvd compounds capable of substituting for fviii(a) |
| WO2024199734A2 (en) | 2023-03-30 | 2024-10-03 | Novo Nordisk A/S | Fusion compounds and uses thereof |
| TW202448921A (zh) * | 2023-05-12 | 2024-12-16 | 丹麥商諾佛 儂迪克股份有限公司 | 長效生長激素受體拮抗劑及其用途 |
| TW202511291A (zh) | 2023-09-11 | 2025-03-16 | 丹麥商諾佛 儂迪克股份有限公司 | 抗ｉｌ－６結構域之抗體 |
| CN118307684B (zh) * | 2024-06-11 | 2024-10-18 | 北京志道生物科技有限公司 | 一种经脂肪酸链修饰的glp-1-fgf21融合蛋白及其制备方法和应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| EP1826216A1 (en) | 1996-08-30 | 2007-08-29 | Novo Nordisk A/S | Glp-1 derivatives |
| US20040259780A1 (en) | 2001-07-30 | 2004-12-23 | Glasebrook Andrew Lawrence | Method for treating diabetes and obesity |
| EP1329227A1 (en) | 2002-01-22 | 2003-07-23 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells |
| US7452966B2 (en) | 2003-06-12 | 2008-11-18 | Eli Lilly And Company | GLP-1 analog fusion proteins |
| EP2932981B1 (en) | 2003-09-19 | 2021-06-16 | Novo Nordisk A/S | Albumin-binding derivatives of GLP-1 |
| TW200522976A (en) | 2003-09-19 | 2005-07-16 | Novo Nordisk As | Novel plasma protein affinity tags |
| AU2004303783A1 (en) * | 2003-12-10 | 2005-07-07 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| CN101665538A (zh) | 2003-12-18 | 2010-03-10 | 诺沃挪第克公司 | 与白蛋白样物质相连的新glp-1类似物 |
| JP2007531715A (ja) | 2004-03-17 | 2007-11-08 | イーライ リリー アンド カンパニー | グリコール結合ｆｇｆ−２１化合物 |
| ATE444306T1 (de) * | 2004-05-13 | 2009-10-15 | Lilly Co Eli | Fgf-21-fusionsproteine |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| EP2292272A3 (en) * | 2004-07-08 | 2011-10-26 | Novo Nordisk A/S | Polypeptide protracting tags comprising a tetrazole moiety |
| EP1789443A1 (en) | 2004-09-02 | 2007-05-30 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| BRPI0514790A (pt) | 2004-09-02 | 2008-06-24 | Lilly Co Eli | muteìna de fgf-21 de humano, ou um seu peptìdeo biologicamente ativo, método para produzir a muteìna, composição farmacêutica, e, uso da muteìna de fgf-21 de humano |
| SI2586456T1 (sl) | 2004-10-29 | 2016-05-31 | Ratiopharm Gmbh | Preoblikovanje in glikopegliacija fibroblastnega rastnega faktorja (FGF) |
| US7655627B2 (en) | 2004-12-14 | 2010-02-02 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| JP2008528487A (ja) | 2005-01-21 | 2008-07-31 | イーライ リリー アンド カンパニー | 心臓血管疾患を治療する方法 |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| EP2101822A2 (en) | 2007-01-18 | 2009-09-23 | Novo Nordisk A/S | Use of peptides in combination with surgical intervention for the treatment of obesity |
| CN101663046B (zh) | 2007-03-30 | 2017-07-28 | Ambrx公司 | 经修饰fgf‑21多肽和其用途 |
| EP2068909B1 (en) | 2007-03-30 | 2012-04-25 | Ambrx, Inc. | Modified fgf-21 polypeptides and their uses |
| EP3260129A1 (en) | 2007-08-03 | 2017-12-27 | Eli Lilly and Company | An fgf-21 compound and a glp-1 compound for use in the treatment of obesity |
| WO2009030771A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| CN100587073C (zh) | 2008-03-24 | 2010-02-03 | 吉林农大生物反应器工程有限公司 | 人成纤维细胞生长因子-21的重组表达 |
| JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| AU2009302318A1 (en) * | 2008-10-10 | 2010-04-15 | Amgen Inc. | FGF21 mutants and uses thereof |
| WO2010065439A1 (en) | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants of fibroblast growth factor 21 |
| CN102361647B (zh) * | 2009-01-23 | 2018-02-16 | 诺沃-诺迪斯克有限公司 | 具有白蛋白结合剂a‑b‑c‑d‑e‑的fgf21衍生物及其应用 |
| WO2010129600A2 (en) | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
| TWI436776B (zh) | 2009-05-05 | 2014-05-11 | Amgen Inc | Ｆｇｆ２１突變體及其用途 |
| JP2012529463A (ja) | 2009-06-11 | 2012-11-22 | ノヴォ ノルディスク アー／エス | ２型糖尿病を治療するための、ｇｌｐ−１とｆｇｆ２１との組合せ |
| US20120035099A1 (en) * | 2009-06-11 | 2012-02-09 | Novo Nordisk A/S | Fgf21 analogues and derivatives |
| WO2011154349A2 (en) * | 2010-06-08 | 2011-12-15 | Novo Nordisk A/S | Fgf21 analogues and derivatives |
| WO2012010553A1 (en) * | 2010-07-20 | 2012-01-26 | Novo Nordisk A/S | N-terminal modified fgf21 compounds |
| WO2013033452A2 (en) * | 2011-08-31 | 2013-03-07 | Amgen Inc. | Method of treating or ameliorating type 1 diabetes using fgf21 |
| WO2014037373A1 (en) * | 2012-09-07 | 2014-03-13 | Sanofi | Fusion proteins for treating a metabolic syndrome |
| US9925242B2 (en) * | 2012-12-27 | 2018-03-27 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of nonalcoholic steatohepatitis |
-
2015
- 2015-12-22 TW TW104143111A patent/TWI681966B/zh active
- 2015-12-22 DK DK15817847.5T patent/DK3236991T3/da active
- 2015-12-22 PL PL15817847T patent/PL3236991T3/pl unknown
- 2015-12-22 RU RU2017125050A patent/RU2729011C2/ru active
- 2015-12-22 MX MX2017007458A patent/MX377044B/es active IP Right Grant
- 2015-12-22 HU HUE15817847 patent/HUE044783T2/hu unknown
- 2015-12-22 SI SI201530859T patent/SI3236991T1/sl unknown
- 2015-12-22 JP JP2017533789A patent/JP6727210B2/ja active Active
- 2015-12-22 HR HRP20191292TT patent/HRP20191292T1/hr unknown
- 2015-12-22 PT PT15817847T patent/PT3236991T/pt unknown
- 2015-12-22 MY MYPI2017701848A patent/MY181181A/en unknown
- 2015-12-22 EP EP15817847.5A patent/EP3236991B1/en active Active
- 2015-12-22 AR ARP150104256A patent/AR103246A1/es active IP Right Grant
- 2015-12-22 CN CN201580069436.9A patent/CN107108709B/zh active Active
- 2015-12-22 WO PCT/EP2015/080969 patent/WO2016102562A1/en not_active Ceased
- 2015-12-22 AU AU2015371056A patent/AU2015371056B2/en active Active
- 2015-12-22 KR KR1020177017682A patent/KR102427527B1/ko active Active
- 2015-12-22 HK HK18105587.8A patent/HK1246156B/en unknown
- 2015-12-22 TW TW108144310A patent/TWI708781B/zh active
- 2015-12-22 ES ES15817847T patent/ES2742503T3/es active Active
- 2015-12-22 RS RSP20191106 patent/RS59154B1/sr unknown
-
2017
- 2017-03-08 US US15/453,617 patent/US9744213B2/en active Active
- 2017-05-22 IL IL252438A patent/IL252438B/en unknown
- 2017-06-01 ZA ZA2017/03768A patent/ZA201703768B/en unknown
- 2017-06-06 SA SA517381673A patent/SA517381673B1/ar unknown
- 2017-07-07 US US15/643,543 patent/US9895417B2/en active Active
- 2017-12-21 US US15/849,920 patent/US10124039B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017007458A (es) | Derivados del factor 21 de crecimiento de fibroblastos (fgf21) y sus usos. | |
| MX2017015105A (es) | Compuestos del peptido yy (pyy) selectivos y sus usos. | |
| CL2018003319A1 (es) | Compuestos de mic-1 y usos de estos. | |
| SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| MX369818B (es) | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. | |
| NI201700101A (es) | Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina | |
| MX2016011468A (es) | Inhibidores de calicreína plasmática humana. | |
| CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
| UY37742A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| EA201791696A1 (ru) | Композиция для лечения веноокклюзионной болезни печени | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| CL2019002218A1 (es) | Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| CL2021000129A1 (es) | Apirasas solubilizadas, métodos y usos | |
| MX2018003930A (es) | Inhibidores de calicreína plasmática humana. | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| JOP20170137B1 (ar) | صيغ قابلة للحقن متوازنة فسيولوجياً من فوسنيتوبيتانت | |
| MX2020007760A (es) | Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano. | |
| CO2019009000A2 (es) | Combinaciones farmacéuticas para tratar cáncer | |
| CL2019002480A1 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
| UY36732A (es) | Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet | |
| CY1123041T1 (el) | Συνδυασμος κανρενοατης και εξενατιδης | |
| AR102295A1 (es) | Compuesto derivado de pirazolina y su uso en un régimen de dosificación semanal contra inflamación y dolor derivados de enfermedad articular degenerativa en mamíferos | |
| CO2018008626A2 (es) | Formulaciones de oritavancina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |